Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

BACKGROUND: Baricitinib, an oral-administrated selective inhibitor of the JAK1 and JAK2, is recently approved for rheumatoid arthritis (RA) treatment. With the aim to provide some insights on the clinical safety, the current study mainly focused on the effect of baricitinib on low-density lipoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Chengfeng, Zhao, Xiang, She, Lang, Shi, Zhihua, Deng, Ziwei, Tan, Liming, Tu, Xiaojun, Jiang, Shilong, Tang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380020/
https://www.ncbi.nlm.nih.gov/pubmed/30777075
http://dx.doi.org/10.1186/s12944-019-0994-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380020/
https://www.ncbi.nlm.nih.gov/pubmed/30777075
http://dx.doi.org/10.1186/s12944-019-0994-7

Ejemplares similares